Efficacy and Safety of Abrocitinib in Adults With Moderate-to-Severe Atopic Dermatitis After Switching From Dupilumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND)
J Am Acad Dermatol 2022 Apr 15;[EPub Ahead of Print], VY Shi, T Bhutani, L Fonacier, M Deleuran, S Shumack, H Valdez, F Zhang, GL Chan, MC Cameron, NC YinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.